https://www.selleckchem.com/pr....oducts/lonafarnib-sc
The survival rate for patients on ECMO was 40%. The comparative analysis between survivors and non-survivors highlighted that survivors had a significantly shorter mechanical ventilation duration before ECMO (4±2days vs. 9±2days, p=0.01). All the patients who had more than 150h of mechanical ventilation before the application of ECMO ultimately died. The present results suggest that VV-ECMO can be safely utilized in appropriately selected COVID-19 patients with refractory hypoxemia. The main information for clinicians is tha
Like
Comment
Share
